Hypercalcaemia of MalignancyUrgent

Oncology · Ward Pathways · Free — no sign-in

Known myeloma, now confused and constipated — corrected Ca²⁺ 3.6. Volume first, calcitonin for speed, zoledronate for durability.

ABCDE

Confirm corrected/ionised Ca²⁺; 0.9% saline 200–300 mL/h immediately; calcitonin 4 IU/kg SC q12h (works in hours); zoledronic acid 4 mg IV (works in days); treat the malignancy.

  1. Confirm + assess: corrected Ca²⁺ = measured + 0.02×(40 − albumin), or ionised; severity: mild <3.0, moderate 3.0–3.5, severe >3.5 mmol/L — symptoms (confusion, constipation, polyuria) drive urgency
  2. VOLUME FIRST: 0.9% saline 200–300 mL/h targeting urine output 100–150 mL/h — restores GFR and calciuresis; furosemide ONLY after fully volume-repleted if overloaded
  3. Calcitonin — the fast arm: 4 IU/kg SC/IM q12h — onset 2–4 h, drops Ca²⁺ ~0.5 mmol/L; tachyphylaxis after 48 h (bridge only)
  4. Bisphosphonate — the durable arm: zoledronic acid 4 mg IV over 15 min (onset 2–4 days, lasts weeks; renal dose-adjust); severe CKD → denosumab 120 mg SC instead
  5. Special cases: calcitriol-driven (lymphoma/granuloma) → prednisolone 40–60 mg; refractory + CKD/HF → haemodialysis with low-calcium bath
  6. Fix the cause: PTHrP/myeloma workup; disease control (chemo, SCT, radiotherapy) is the only lasting cure; avoid thiazides, lithium, Ca²⁺/vitamin D supplements
Calculators:

Order set

  • Corrected Ca²⁺, phosphate, Mg²⁺, PTH, creatinine
  • 0.9% saline 200–300 mL/h
  • Calcitonin 4 IU/kg SC q12h
  • Zoledronic acid 4 mg IV (or denosumab 120 mg SC if CKD)
  • ECG — QT shortens
  • Strict fluid balance + urine output

Monitor

  • q12–24 hCorrected Ca²⁺ until <3.0 and falling
  • HourlyUrine output — target 100–150 mL/h
  • DailyCreatinine, phosphate, Mg²⁺; confusion score
  • Day 2–4Bisphosphonate effect lands — wean fluids as Ca²⁺ falls

Escalate / ICU

  • Corrected Ca²⁺ >3.5 or severe symptoms at any level
  • Oliguria/AKI
  • Confusion/coma
  • Refractory despite fluids + bisphosphonate — renal consult

Criteria

AdmitCorrected Ca²⁺ ≥3.0 with symptoms, or ≥3.5 regardless
CalcitoninImmediately if severe/symptomatic
Zoledronate4 mg IV — onset 2–4 d, duration weeks
DialysisRefractory hypercalcaemia with CKD/HF

Never

  • Give furosemide before volume repletion — worsens hypercalcaemia and prerenal AKI
  • Give full-dose zoledronate blindly in severe CKD — denosumab 120 mg SC is safer
  • Wait days for bisphosphonate in a symptomatic patient — calcitonin covers the gap

Key

  • Calcitonin = hours, zoledronate = days, denosumab = renal-safe — layer them
  • Correct for albumin or check ionised Ca²⁺ — hypoalbuminaemia hides true levels
  • PTH suppressed + high Ca²⁺ in malignancy = PTHrP or osteolytic (myeloma)
Clinical detail — differentials, red flags, pitfalls, disposition
Red flags
  • Confusion, coma
  • Corrected Ca²⁺ >3.5
  • Short QT on ECG
  • Oliguria
Differentials
  • Primary hyperparathyroidism (check PTH!)
  • Vitamin D toxicity, granulomatous disease
  • Thiazides, lithium, milk-alkali
  • Myeloma vs PTHrP solid tumour
Common mistakes
  • Treating a number without correcting for albumin
  • Fluids forgotten while waiting for zoledronate
  • Hypophosphataemia ignored during repletion
  • No malignancy treatment plan — Ca²⁺ will recur
Disposition & follow-up

Step down when Ca²⁺ <3.0 and stable on maintenance hydration; oncology for disease-modifying therapy; dental review before ongoing bisphosphonates (ONJ risk).

💊 Treatment detail — doses & preparation
0.9% Sodium chloridecrystalloid
DoseBolus 500 mL over 15–30 min, reassess; maintenance 1–1.5 mL/kg/h
Preparation500/1000 mL bags; add KCl only after urine output confirmed
MonitorHyperchloraemic acidosis with large volumes — prefer balanced (LR) for resuscitation
Calcitoninhypocalcaemic agent
Dose4 IU/kg SC/IM q12h (hypercalcaemia) — onset 2–4 h
Preparation100 IU/mL ampoule SC/IM
MonitorCa²⁺ q12 h; tachyphylaxis after 48 h — bridge to bisphosphonate
Zoledronic acidIV bisphosphonate
Dose4 mg IV over ≥15 min (hypercalcaemia, myeloma bone); renal dose-adjust (3–3.5 mg if CrCl 30–60)
Preparation4 mg/5 mL ready solution or vial dilute in 100 mL NS
MonitorCa²⁺, creatinine; hypocalcaemia/hypophosphataemia after; dental review (ONJ)
DenosumabRANKL inhibitor
Dose120 mg SC (hypercalcaemia of malignancy, renal-safe option)
Preparation120 mg/1.7 mL pre-filled syringe SC upper arm/thigh/abdomen
MonitorCa²⁺ (hypocalcaemia — supplement Ca²⁺/D), ONJ risk
📖 Endocrine Society hypercalcaemia guidance + textbook Ch.31Reviewed July 2026

← Febrile Neutropenia  ·  Osteomyelitis →

More Oncology pathways

Part of Oncology in Ward Pathways — open the interactive version.

ICU Decoded — original critical-care and internal-medicine pathways by Dr Javed Akhtar, each cited to a current guideline. For education and quick reference; verify every dose against local protocols before prescribing.

Open the app · Ward Pathways — 113 free cases · ICU Decoded chapters · Aladin Chirag bedside tools

About · Medical disclaimer · Privacy · Contact